Please enable JavaScript to continue using this application.

Compare $IBIO vs $XLO | Chartloom

Compare

$IBIO vs $XLO

iBio Inc · Xilio Therapeutics Inc

IBIO

iBio Inc

XLO

Xilio Therapeutics Inc

Compare $IBIO vs $XLO

Comparing iBio Inc and Xilio Therapeutics Inc

IBIOiBio Inc

XLOXilio Therapeutics Inc

IBIOiBio Inc

Market cap

$43M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-75.0%

YTD performance

-56.9%

52W performance

0.5%

FCF yield

-55.0%

XLOXilio Therapeutics Inc

Market cap

$54M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.42x

Rev growth (TTM)

327.3%

YTD performance

-3.8%

52W performance

-23.1%

FCF yield

-113.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IBIO

XLO

Detailed metrics comparison

IBIO

iBio Inc

XLO

Xilio Therapeutics Inc

Market Cap

IBIO$43M

XLO$54M

Enterprise Value

IBIO$-13M

XLO$-82M

Price

IBIO$0.87

XLO$9.05

P/E Ratio

IBION/A

XLON/A

P/S Ratio

IBIO432.71x

XLO0.84x

EV/Sales

IBIO-131.24x

XLO-1.28x

EV/EBITDA

IBIO0.00x

XLO0.00x

P/B Ratio

IBIO0.80x

XLO0.82x

P/FCF Ratio

IBION/A

XLON/A

EV/FCF

IBIO0.55x

XLO1.34x

PEG Ratio

IBION/A

XLON/A

Forward P/E (NTM)

IBION/A

XLON/A

Forward P/S (NTM)

IBION/A

XLO3.42x

Revenue (TTM)

IBIO$100K

XLO$64M

Revenue Growth (YoY)

IBIO-75.0%

XLO327.3%

Forward Rev Growth

IBIO33.3%

XLO-34.2%

Gross Margin (TTM)

IBIO52.1%

XLO0.0%

Operating Margin (TTM)

IBIO0.0%

XLO0.0%

EBITDA Margin (TTM)

IBIO-24492.0%

XLO-46.9%

Net Margin (TTM)

IBIO-33044.0%

XLO-34.1%

FCF Margin (TTM)

IBIO-23796.0%

XLO-95.6%

Net Income (TTM)

IBIO$-33M

XLO$-22M

FCF (TTM)

IBIO$-24M

XLO$-61M

EPS (TTM)

IBIO-$0.23

XLO-$1.12

ROE (TTM)

IBIO-4792.0%

XLO-923.0%

ROA (TTM)

IBIO-4216.0%

XLO-1441.0%

ROIC (TTM)

IBIO-4779.0%

XLO-923.0%

Cash

IBIO$56M

XLO$136M

Debt

IBIO$0

XLO$0

Net Cash/Debt

IBIO$56M

XLO$136M

Current Ratio (TTM)

IBIO7.85x

XLO4.25x

Quick Ratio (TTM)

IBIO7.59x

XLO4.15x

Debt/Equity (TTM)

IBIO0.91x

XLO0.00x

Debt/Assets (TTM)

IBIO0.0%

XLO0.0%

Interest Coverage (TTM)

IBION/A

XLON/A

Net Debt/EBITDA (TTM)

IBIO0.00x

XLO0.00x

Beta

IBIO1.42

XLO-0.12

52W Performance

IBIO0.5%

XLO-23.1%

YTD Performance

IBIO-56.9%

XLO-3.8%

% from 52W High

IBIO-77.2%

XLO-28.1%

% from 52W Low

IBIO11.5%

XLO40.0%

Asset Turnover (TTM)

IBIO0.01x

XLO0.42x

FCF Yield (TTM)

IBIO-55.0%

XLO-113.2%

Earnings Yield (TTM)

IBIO-76.4%

XLO-40.3%

Dividend Yield (TTM)

IBION/A

XLON/A

Rule of 40

IBIO-23,871.0

XLO231.7

EV/GP/RG

IBION/A

XLON/A

Ticker research

View IBIO research View XLO research

Metric	IBIO iBio Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$43M	$54M
Enterprise Value	$-13M	$-82M
Price	$0.87	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	432.71x	0.84x
EV/Sales	-131.24x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.80x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	0.55x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$100K	$64M
Revenue Growth (YoY)	-75.0%	327.3%
Forward Rev Growth	33.3%	-34.2%
Profitability
Gross Margin (TTM)	52.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24492.0%	-46.9%
Net Margin (TTM)	-33044.0%	-34.1%
FCF Margin (TTM)	-23796.0%	-95.6%
Net Income (TTM)	$-33M	$-22M
FCF (TTM)	$-24M	$-61M
EPS (TTM)	-$0.23	-$1.12
ROE (TTM)	-4792.0%	-923.0%
ROA (TTM)	-4216.0%	-1441.0%
ROIC (TTM)	-4779.0%	-923.0%
Financial Health
Cash	$56M	$136M
Debt	$0	$0
Net Cash/Debt	$56M	$136M
Current Ratio (TTM)	7.85x	4.25x
Quick Ratio (TTM)	7.59x	4.15x
Debt/Equity (TTM)	0.91x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	-0.12
52W Performance	0.5%	-23.1%
YTD Performance	-56.9%	-3.8%
% from 52W High	-77.2%	-28.1%
% from 52W Low	11.5%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.42x
FCF Yield (TTM)	-55.0%	-113.2%
Earnings Yield (TTM)	-76.4%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-23,871.0	231.7
EV/GP/RG	N/A	N/A
Ticker research	View IBIO research	View XLO research

Valuation

P/S Ratio

XLO

0.84x

IBIO

432.71x

EV/FCF

IBIO

0.55x

XLO

1.34x

Growth & revenue

Revenue Growth TTM

XLO

327.3%

IBIO

-75.0%

Forward Revenue Growth

IBIO

33.3%

XLO

-34.2%

Profitability & performance

Gross Margin

IBIO

52.1%

XLO

0.0%

ROE

XLO

-923.0%

IBIO

-4792.0%

FCF Yield %

IBIO

-55.0%

XLO

-113.2%

52-Week Performance

IBIO

0.5%

XLO

-23.1%

Detailed metrics comparison

IBIO

iBio Inc

XLO

Xilio Therapeutics Inc

Market Cap

IBIO$43M

XLO$54M

Enterprise Value

IBIO$-13M

XLO$-82M

Price

IBIO$0.87

XLO$9.05

P/E Ratio

IBION/A

XLON/A

P/S Ratio

IBIO432.71x

XLO0.84x

EV/Sales

IBIO-131.24x

XLO-1.28x

EV/EBITDA

IBIO0.00x

XLO0.00x

P/B Ratio

IBIO0.80x

XLO0.82x

P/FCF Ratio

IBION/A

XLON/A

EV/FCF

IBIO0.55x

XLO1.34x

PEG Ratio

IBION/A

XLON/A

Forward P/E (NTM)

IBION/A

XLON/A

Forward P/S (NTM)

IBION/A

XLO3.42x

Revenue (TTM)

IBIO$100K

XLO$64M

Revenue Growth (YoY)

IBIO-75.0%

XLO327.3%

Forward Rev Growth

IBIO33.3%

XLO-34.2%

Gross Margin (TTM)

IBIO52.1%

XLO0.0%

Operating Margin (TTM)

IBIO0.0%

XLO0.0%

EBITDA Margin (TTM)

IBIO-24492.0%

XLO-46.9%

Net Margin (TTM)

IBIO-33044.0%

XLO-34.1%

FCF Margin (TTM)

IBIO-23796.0%

XLO-95.6%

Net Income (TTM)

IBIO$-33M

XLO$-22M

FCF (TTM)

IBIO$-24M

XLO$-61M

EPS (TTM)

IBIO-$0.23

XLO-$1.12

ROE (TTM)

IBIO-4792.0%

XLO-923.0%

ROA (TTM)

IBIO-4216.0%

XLO-1441.0%

ROIC (TTM)

IBIO-4779.0%

XLO-923.0%

Cash

IBIO$56M

XLO$136M

Debt

IBIO$0

XLO$0

Net Cash/Debt

IBIO$56M

XLO$136M

Current Ratio (TTM)

IBIO7.85x

XLO4.25x

Quick Ratio (TTM)

IBIO7.59x

XLO4.15x

Debt/Equity (TTM)

IBIO0.91x

XLO0.00x

Debt/Assets (TTM)

IBIO0.0%

XLO0.0%

Interest Coverage (TTM)

IBION/A

XLON/A

Net Debt/EBITDA (TTM)

IBIO0.00x

XLO0.00x

Beta

IBIO1.42

XLO-0.12

52W Performance

IBIO0.5%

XLO-23.1%

YTD Performance

IBIO-56.9%

XLO-3.8%

% from 52W High

IBIO-77.2%

XLO-28.1%

% from 52W Low

IBIO11.5%

XLO40.0%

Asset Turnover (TTM)

IBIO0.01x

XLO0.42x

FCF Yield (TTM)

IBIO-55.0%

XLO-113.2%

Earnings Yield (TTM)

IBIO-76.4%

XLO-40.3%

Dividend Yield (TTM)

IBION/A

XLON/A

Rule of 40

IBIO-23,871.0

XLO231.7

EV/GP/RG

IBION/A

XLON/A

Ticker research

View IBIO research View XLO research

Metric	IBIO iBio Inc	XLO Xilio Therapeutics Inc
Market & Valuation
Market Cap	$43M	$54M
Enterprise Value	$-13M	$-82M
Price	$0.87	$9.05
P/E Ratio	N/A	N/A
P/S Ratio	432.71x	0.84x
EV/Sales	-131.24x	-1.28x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.80x	0.82x
P/FCF Ratio	N/A	N/A
EV/FCF	0.55x	1.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.42x
Revenue & Growth
Revenue (TTM)	$100K	$64M
Revenue Growth (YoY)	-75.0%	327.3%
Forward Rev Growth	33.3%	-34.2%
Profitability
Gross Margin (TTM)	52.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24492.0%	-46.9%
Net Margin (TTM)	-33044.0%	-34.1%
FCF Margin (TTM)	-23796.0%	-95.6%
Net Income (TTM)	$-33M	$-22M
FCF (TTM)	$-24M	$-61M
EPS (TTM)	-$0.23	-$1.12
ROE (TTM)	-4792.0%	-923.0%
ROA (TTM)	-4216.0%	-1441.0%
ROIC (TTM)	-4779.0%	-923.0%
Financial Health
Cash	$56M	$136M
Debt	$0	$0
Net Cash/Debt	$56M	$136M
Current Ratio (TTM)	7.85x	4.25x
Quick Ratio (TTM)	7.59x	4.15x
Debt/Equity (TTM)	0.91x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.42	-0.12
52W Performance	0.5%	-23.1%
YTD Performance	-56.9%	-3.8%
% from 52W High	-77.2%	-28.1%
% from 52W Low	11.5%	40.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.42x
FCF Yield (TTM)	-55.0%	-113.2%
Earnings Yield (TTM)	-76.4%	-40.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-23,871.0	231.7
EV/GP/RG	N/A	N/A
Ticker research	View IBIO research	View XLO research